/KYMR
KYMR Stock - Kymera Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$83.99+5.48%
+$4.36 (+5.48%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).90
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.29
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+19.8%upside
Target: $100.62
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KYMR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$83.15 – $84.83
TARGET (TP)$100.60
STOP LOSS$77.27
RISK/REWARD1:2.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.29
52W High$103.00
52W Low$19.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $47.07M | $78.59M | $46.83M | $72.83M | $34.03M |
| Gross Profit | $47.07M | $78.59M | $46.83M | $72.83M | $34.03M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-261,635,000 | $-165,530,000 | $-161,256,000 | $-100,530,000 | $-46,304,000 |
| Net Income | $-223,858,000 | $-146,962,000 | $-154,808,000 | $-100,217,000 | $-45,593,000 |
| Net Margin | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% |
| EPS | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-0.99 |
Company Overview
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
19
86%
Hold / Neutral
3
14%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
19 Bullish3 Neutral/Bearish
Price Targets
$57
Average Target
↓ 32.0% Downside
Now
$26
Low
$57
Average
$90
High
Based on 28 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 3rd 2025 | Guggenheim | Resumed | Buy | $90 |
| October 24th 2025 | B. Riley Securities | Reiterated | Buy | $80← $60 |
| October 21st 2025 | Mizuho | Initiation | Outperform | $81 |
| September 18th 2025 | H.C. Wainwright | Reiterated | Buy | $70← $60 |
| September 17th 2025 | Barclays | Initiation | Overweight | $60 |
| September 16th 2025 | RBC Capital Mkts | Initiation | Outperform | $70 |
| July 30th 2025 | B. Riley Securities | Resumed | Buy | $60 |
| July 3rd 2025 | Morgan Stanley | Resumed | Overweight | $70 |
| June 3rd 2025 | Morgan Stanley | Upgrade | Overweight | $79 |
| June 3rd 2025 | B. Riley Securities | Upgrade | Buy | $60 |
| June 2nd 2025 | BofA Securities | Upgrade | Buy | $51 |
| May 20th 2025 | Stifel | Resumed | Buy | $55 |
| March 13th 2025 | Citigroup | Initiation | Buy | $52 |
| December 10th 2024 | BTIG Research | Initiation | Buy | $60 |
| December 6th 2024 | BMO Capital Markets | Initiation | Market Perform | $55 |
Earnings History & Surprises
KYMRBeat Rate
33%
Last 18 quarters
Avg Surprise
-19.4%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-0.90
Q4 2025
EPS Surprise History
Q1 24
+43.2%
$-0.25vs$-0.44
Q2 24
+5.5%
$-0.69vs$-0.73
Q3 24
+15.9%
$-0.58vs$-0.69
Q4 24
+1.2%
$-0.82vs$-0.83
Q1 25
-15.8%
$-0.88vs$-0.76
Q2 25
+10.9%
$-0.82vs$-0.92
Q3 25
-14.5%
$-0.95vs$-0.83
Q4 25
-26.8%
$-0.90vs$-0.71
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.78 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.71 | $-0.90 | -26.8% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.83 | $-0.95 | -14.5% | ✗ MISS |
Q2 2025 | May 9, 2025 | $-0.92 | $-0.82 | +10.9% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.76 | $-0.88 | -15.8% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-0.83 | $-0.82 | +1.2% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.69 | $-0.58 | +15.9% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.73 | $-0.69 | +5.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.44 | $-0.25 | +43.2% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.73 | $-0.90 | -23.3% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.70 | $-0.67 | +4.3% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.69 | $-0.70 | -1.4% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.57 | $-0.60 | -5.3% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.70 | $-0.79 | -12.9% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.68 | $-0.78 | -14.7% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.67 | $-0.71 | -6.0% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.36 | $-0.66 | -83.3% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.34 | $-0.56 | -64.7% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $-0.21 | $-0.55 | -161.9% | ✗ MISS |
Latest News
RBC Capital Maintains Outperform on Kymera Therapeutics, Raises Price Target to $103
📈 PositiveBenzinga•Dec 16, 2025, 02:00 PM
Stephens & Co. Maintains Overweight on Kymera Therapeutics, Raises Price Target to $110
📈 PositiveBenzinga•Dec 11, 2025, 01:52 PM
Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $120
📈 PositiveBenzinga•Dec 11, 2025, 01:11 PM
Kymera Therapeutics Plans KT-621 BROADEN2 Atopic Dermatitis And BREADTH Asthma Phase 2b Trials Following FDA Fast Track Designation
📈 PositiveBenzinga•Dec 11, 2025, 12:07 PM
JP Morgan Maintains Overweight on Kymera Therapeutics, Raises Price Target to $125
📈 PositiveBenzinga•Dec 10, 2025, 03:58 PM
Kymera Therapeutics shares are trading higher. The company announced the pricing of a $602.0M underwritten public offering of 7,000,000 shares at $86 each.
📈 PositiveBenzinga•Dec 10, 2025, 02:24 PM
Reported Earlier, Kymera Therapeutics Prices Upsized $602M Public Offering Of 7M Common Shares At $86 Each, Funding Oral Small Molecule Degrader Pipeline
📈 PositiveBenzinga•Dec 10, 2025, 07:53 AM
Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $110
📈 PositiveBenzinga•Dec 9, 2025, 07:51 PM•Also:
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $116
📈 PositiveBenzinga•Dec 9, 2025, 06:04 PM
Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $116
📈 PositiveBenzinga•Dec 9, 2025, 05:41 PM
Oppenheimer Maintains Outperform on Kymera Therapeutics, Raises Price Target to $120
📈 PositiveBenzinga•Dec 9, 2025, 05:32 PM
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $127
📈 PositiveBenzinga•Dec 9, 2025, 05:19 PM
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $119
📈 PositiveBenzinga•Dec 9, 2025, 04:40 PM•Also:
Piper Sandler Reiterates Overweight on Kymera Therapeutics, Raises Price Target to $125
📈 PositiveBenzinga•Dec 9, 2025, 03:44 PM
HC Wainwright & Co. Maintains Buy on Kymera Therapeutics, Raises Price Target to $134
📈 PositiveBenzinga•Dec 9, 2025, 03:28 PM
Leerink Partners Maintains Outperform on Kymera Therapeutics, Raises Price Target to $118
📈 PositiveBenzinga•Dec 9, 2025, 01:10 PM
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $112
📈 PositiveBenzinga•Dec 9, 2025, 12:13 PM
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $138
📈 PositiveBenzinga•Dec 9, 2025, 10:31 AM
KYMR stock has given up its prior loss. Kymera Therapeutics shares were trading lower after the company announced a $500 million proposed public offering.
➖ NeutralBenzinga•Dec 8, 2025, 10:56 PM
Kymera Therapeutics shares are trading lower after the company announced a $500 million proposed public offering.
📉 NegativeBenzinga•Dec 8, 2025, 09:42 PM
Frequently Asked Questions about KYMR
What is KYMR's current stock price?
Kymera Therapeutics, Inc. (KYMR) is currently trading at $83.99 per share. The stock has moved +5.48% today.
What is the analyst price target for KYMR?
The average analyst price target for KYMR is $100.60, based on 1 analyst.
What sector is Kymera Therapeutics, Inc. in?
Kymera Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KYMR's market cap?
Kymera Therapeutics, Inc. has a market capitalization of $6.04 billion, making it a mid-cap company.
Does KYMR pay dividends?
No, Kymera Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
ACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
ACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to KYMR for comparison